<DOC>
	<DOCNO>NCT00559533</DOCNO>
	<brief_summary>This study determine maximum tolerate dose optimal associate 4 weekly dosing schedule RO5045337 , administer monotherapy patient advance solid tumor . A first cohort patient receive start dose 20mg/m2/day , daily 10 day 28 day cycle . Subsequent cohort patient receive dose escalation , possible change dose schedule , base tolerability pharmacokinetic knowledge gain prior treatment cohort . The anticipated time study treatment disease progression intolerable toxicity .</brief_summary>
	<brief_title>A Study RO5045337 RG7112 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>adult patient , &gt; =18 year age ; solid tumor malignancy ; fail prior therapy , standard therapy available ; ECOG performance status 02. patient receive agent therapy treat malignancy ; preexist gastrointestinal disorder may interfere absorption drug ; clinically significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>